The Blood and Cell Advocacy Register (BCAR) is a newly launched consortium that aims to revolutionize the development and commercialization of advanced therapy medicinal products (ATMPs). Formed in December 2024, BCAR brings together experts and organizations from the blood and cell industries to
The advancements in muscle regeneration technology by Swiss biotech company MUVON Therapeutics are making waves, especially in the realm of treating stress urinary incontinence in women. This breakthrough holds the potential to improve the quality of life for millions while extending healthspan.
In a groundbreaking partnership aimed at revolutionizing the production processes for stem cell-based therapies, Mytos has joined forces with Aspen Neuroscience to enhance the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs). These cells are integral to Aspen’s ANPD001, an
Penn Medicine’s Center for Cellular Immunotherapies (CCI) is at the forefront of revolutionizing cancer treatment through CAR (chimeric antigen receptor) T cell therapy. This innovative approach harnesses the power of the patient’s own immune system to target and destroy cancer cells, offering new
CAR-T cell therapy has emerged as a groundbreaking approach in cancer treatment, leveraging the body's immune system to target and destroy cancer cells. Since its inception in 2017, this innovative therapy has rapidly evolved, with numerous products reaching commercialization and receiving
The rise in skin cancer cases worldwide has necessitated the exploration of innovative and more efficient treatments. Among the promising solutions is immunotherapy for cancer, a revolutionary method known for its effectiveness. However, this approach is often expensive and may cause severe side
